BACKGROUND: The widely used 23-valent plain polysaccharide vaccine (23vP) has limited effectiveness, produces short-lived immune responses, and induces attenuated antibody production after subsequent challenge with pneumococcal vaccines. Our goal was to examine whether priming with the 7-valent pneumococcal conjugate vaccine (PCV7) could enhance the immunogenicity of 23vP for the PCV7 serotypes and to investigate whether 23vP induced hyporesponsiveness could be overcome using PCV7. METHODS: We conducted an open-label randomized study that compared 3 vaccine schedules, each of which consisted of 2 doses of PCV7 and 1 dose of 23vP (23vP-PCV7-PCV7, PCV7-23vP-PCV7, PCV7-PCV7-23vP) administered over a 1-year period in a cohort of 348 adults 50-70 years of age. All vaccines were administered intramuscularly and were given 6 months apart. Blood samples were obtained prior to and 1 month after each vaccination. RESULTS:23vP administered after priming with 2 doses of PCV7 produced significantly higher antibody concentrations for 3 of the 7 PCV7 serotypes, compared with vaccination with a single dose of 23vP; however, the same immunogenicity could be achieved with a single dose of PCV7. Prior vaccination with 23vP attenuated the antibody response to subsequent PCV7, which was not restored by additional doses of PCV7. CONCLUSION: In adults, vaccination schedules combining PCV7 and 23vP do not provide improved immunogenicity over the use of a single dose of 23vP for most of the serotypes contained in PCV7.
RCT Entities:
BACKGROUND: The widely used 23-valent plain polysaccharide vaccine (23vP) has limited effectiveness, produces short-lived immune responses, and induces attenuated antibody production after subsequent challenge with pneumococcal vaccines. Our goal was to examine whether priming with the 7-valent pneumococcal conjugate vaccine (PCV7) could enhance the immunogenicity of 23vP for the PCV7 serotypes and to investigate whether 23vP induced hyporesponsiveness could be overcome using PCV7. METHODS: We conducted an open-label randomized study that compared 3 vaccine schedules, each of which consisted of 2 doses of PCV7 and 1 dose of 23vP (23vP-PCV7-PCV7, PCV7-23vP-PCV7, PCV7-PCV7-23vP) administered over a 1-year period in a cohort of 348 adults 50-70 years of age. All vaccines were administered intramuscularly and were given 6 months apart. Blood samples were obtained prior to and 1 month after each vaccination. RESULTS: 23vP administered after priming with 2 doses of PCV7 produced significantly higher antibody concentrations for 3 of the 7 PCV7 serotypes, compared with vaccination with a single dose of 23vP; however, the same immunogenicity could be achieved with a single dose of PCV7. Prior vaccination with 23vP attenuated the antibody response to subsequent PCV7, which was not restored by additional doses of PCV7. CONCLUSION: In adults, vaccination schedules combining PCV7 and 23vP do not provide improved immunogenicity over the use of a single dose of 23vP for most of the serotypes contained in PCV7.
Authors: Christine Juergens; Pierre J T de Villiers; Keymanthri Moodley; Deepthi Jayawardene; Kathrin U Jansen; Daniel A Scott; Emilio A Emini; William C Gruber; Beate Schmoele-Thoma Journal: Hum Vaccin Immunother Date: 2014-02-27 Impact factor: 3.452
Authors: Paul V Licciardi; Fiona M Russell; Anne Balloch; Robert L Burton; Moon H Nahm; Gwendolyn Gilbert; Mimi L K Tang; Edward K Mulholland Journal: Vaccine Date: 2014-03-06 Impact factor: 3.641
Authors: Hugh Adler; Esther L German; Elena Mitsi; Elissavet Nikolaou; Sherin Pojar; Caz Hales; Rachel Robinson; Victoria Connor; Helen Hill; Angela D Hyder-Wright; Lepa Lazarova; Catherine Lowe; Emma L Smith; India Wheeler; Seher R Zaidi; Simon P Jochems; Dessi Loukov; Jesús Reiné; Carla Solórzano-Gonzalez; Polly de Gorguette d'Argoeuves; Tessa Jones; David Goldblatt; Tao Chen; Stephen J Aston; Neil French; Andrea M Collins; Stephen B Gordon; Daniela M Ferreira; Jamie Rylance Journal: Am J Respir Crit Care Med Date: 2021-03-01 Impact factor: 21.405